Results 111 to 120 of about 7,354 (172)

Understanding the action of bamocaftor as a potential drug candidate against Cystic Fibrosis Transmembrane Regulator protein: A computational approach. [PDF]

PLoS One
Patel N, Sarkar S, V M BM, Kashyap I, Thiruselvam P, Sundararajan V, Lulu Sudhakaran S.   +6 more
europepmc   +1 more source

Effects of CFTR Modulators on <i>Pseudomonas aeruginosa</i> Infections in Cystic Fibrosis. [PDF]

Infect Dis Rep
Pescaru CC, Crișan AF, Marițescu A, Cărunta V, Marc M, Dumitrache-Rujinski Ș, Laitin S, Oancea C.   +7 more
europepmc   +1 more source

ePS05.6 Cessation of pancreatic enzyme replacement therapy (PERT) after initiation of therapy with ivacaftor – a case series

, 2015
Eric Cheah, Elisabetta Venuti, Karen McKay, Kerry Gaskin   +3 more
openalex   +1 more source

Scedosporium infection as a late complication after start of elexacaftor/tezacaftor/ivacaftor: two case reports. [PDF]

Respir Med Case Rep
van Mourik P, van der Hout EC, Luijk HD, Hofland RW, Bruns AHW, Heijerman HGM, Bronsveld I.   +6 more
europepmc   +1 more source

ePS03.4 Improved rate of decline in percent predicted FEV 1 (ppFEV 1 ) is not associated with acute improvement in ppFEV 1 in patients with cystic fibrosis (CF) treated with ivacaftor

, 2016
Edward F. McKone, G. Sawicki, Stefanie J. Millar, D.J. Pasta, Jaime Rubin, Michael W. Konstan, J. Wagener   +6 more
openalex   +1 more source

Long-term Reductions in Inflammation in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor. [PDF]

Ann Am Thorac Soc
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM.   +14 more
europepmc   +1 more source

Development and Validation of a Novel Stability-Indicating RP-HPLC Method for Simultaneous Determination of Tezacaftor and Ivacaftor in Fixed Dose Combination [PDF]

, 2019
Narendra Singh, Parveen Bansal, Mukesh Maithani, Yashpal Singh Chauhan   +3 more
openalex   +1 more source

Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO. [PDF]

J Clin Endocrinol Metab
Chan CL, Shirley Bezerra M, Stefanovski D, Gallop RJ, Walega R, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Narkewicz MR, Rowe SM, Sagel SD, Schwarzenberg SJ, Solomon GM, Stalvey MS, Kelly A.   +16 more
europepmc   +1 more source

Effect of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Liver Enzymes Among Patients With Cystic Fibrosis: A Systematic Review and Meta-Analysis. [PDF]

Gastro Hep Adv
Vongsavath T, Tun KM, Mukhopadhyay D, Lo CH, Singh A, Amin R, Twohig P, Saab S, Manne V.   +8 more
europepmc   +1 more source

Integrating Novel Outcome Measures for Long-Term Evaluation of Lumacaftor-Ivacaftor Therapy in Cystic Fibrosis Patients Homozygous for F508del

Isabella Comello, Francesca Lucca, Silvia Bertolo, Luigi Martinelli, Marco Cipolli, Mirco Ros, Isabella Comello, Francesca Lucca, Silvia Bertolo, Luigi Martinelli, Marco Cipolli, Mirco Ros   +11 more
openalex   +1 more source